Table 2.
Characteristics of PCI procedure in patients randomized to trimetazidine or standard therapy prior to PCI.
| Variable | TMZ + n = 36 | TMZ − n = 35 | p-value |
|---|---|---|---|
| Coronary artery treated | 0.662 | ||
| LAD n (%) | 15 (41.7) | 17 (48.5) | — |
| Cx-OM n (%) | 12 (33.3) | 11 (31.4) | — |
| RCA n (%) | 9 (25.0) | 7 (20.0) | — |
| Multivessel disease n (%) | 16 (44.4) | 12 (34.3) | 0.264 |
| RVD before PCI (mm) | 2.8 ± 0.2 | 2.9 ± 0.4 | 0.373 |
| DS before PCI (%) | 71 ± 8 | 69 ± 9 | 0.425 |
| MLD before PCI (mm) | 1.2 ± 0.3 | 1.4 ± 0.3 | 0.136 |
| Residual DS after PCI (%) | 13 ± 9 | 17 ± 12 | 0.089 |
| Total stent length (mm) | 21.5 ± 4.8 | 22.7 ± 6.2 | 0.421 |
| Stent diameter (mm) | 3.2 ± 0.4 | 3.1 ± 0.4 | 0.588 |
| Postdilatation n (%) | 15 (41.7) | 13 (37.1) | 0.753 |
| Clopidogrel n (%) | 29 (80.6) | 30 (85.7) | 0.202 |
| Ticagrelor n (%) | 7 (19.4) | 5 (14.3) | 0.274 |
| Beta blockers n (%) | 35 (97.2) | 31 (88.5) | 0.170 |
| ACE inhibitor n (%) | 27 (75.0) | 32 (91.4) | 0.062 |
| Statin n (%) | 36 (100) | 35 (100) | 0.746 |
ACE, angiotensin converting enzyme; Cx, circumflex artery; DS, diameter stenosis; LAD, left anterior descending; MLD, minimal lumen diameter; OM, obtuse marginal; RCA, right coronary artery; RVD, reference vessel diameter.